TUB-040 for recurrent uterine cancer after chemotherapy and immunotherapy
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new drug called TUB-040 for people with uterine cancer (specifically serous or endometrioid type) that has returned or grown after standard treatments like chemotherapy and immunotherapy. The drug is designed to target and kill cancer cells with less harm to healthy cells, and the study hopes to help patients who have run out of standard options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of uterine cancer called serous or endometrioid, and it has come back or grown despite treatment.
- You have already had at least one round of chemotherapy (platinum-based) and one round of immunotherapy (like pembrolizumab or dostarlimab).
- Your cancer must show growth on a scan after your last treatment.
- You are at least 18 years old and able to do daily activities with little or no help.
- You need to have a tissue sample available for testing, or be willing to have a new biopsy.
- You must have normal organ function (liver, kidneys, blood counts) and no major health conditions that would make the trial risky.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called TUB-040, given together with standard ovarian cancer drugs like carboplatin and bevacizumab. It is for women with ovarian cancer that has returned after responding to platinum-based chemotherapy and is growing again. The goal is to see if this combination can help control the cancer.
This trial tests an experimental drug called TUB-040 for people with advanced non-small cell lung cancer that has spread or cannot be removed by surgery. The drug is designed to target and attack cancer cells while sparing healthy tissue, potentially slowing the cancer's growth.
This trial is testing an experimental therapy against standard chemotherapy for people with endometrial cancer that has come back. The study looks for a certain protein (HER2) on cancer cells to decide which treatment group you may be in.
This Phase 1/2 study tests targeted drug(s) for endometrial cancer that has come back or never fully went away after prior treatments. You may be eligible if your tumor can be tested for specific biomarkers and your health allows treatment safely.
This study tests a new drug called TUB-040 for people with ovarian cancer that has stopped responding to platinum chemotherapy, or with a type of lung cancer that has returned or spread. The drug is designed to target cancer cells and deliver a powerful anti-cancer agent directly to them, potentially slowing the disease.
This trial tests a new drug called TUB-030 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective.
Hear when a new Uterine Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.